178 related articles for article (PubMed ID: 12529099)
1. Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community.
George JN; Vesely SK
Ann Intern Med; 2003 Jan; 138(2):152-3. PubMed ID: 12529099
[No Abstract] [Full Text] [Related]
2. Summaries for patients. Treatment of refractory thrombotic thrombocytopenic purpura.
Ann Intern Med; 2003 Jan; 138(2):I38. PubMed ID: 12529111
[No Abstract] [Full Text] [Related]
3. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA
Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide.
Fakhouri F; Teixeira L; Delarue R; Grünfeld JP; Veyradier A
Ann Intern Med; 2004 Feb; 140(4):314-5. PubMed ID: 14970167
[No Abstract] [Full Text] [Related]
5. Rituximab for TTP.
Scott SM; Szczepiorkowski ZM
Am J Hematol; 2005 Sep; 80(1):87-8. PubMed ID: 16138332
[No Abstract] [Full Text] [Related]
6. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab.
Hagel S; Jantsch J; Budde U; Kalden JR; Eckardt KU; Veelken R
Thromb Haemost; 2008 Jul; 100(1):151-3. PubMed ID: 18612551
[No Abstract] [Full Text] [Related]
7. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura.
Foley SR; Webert K; Arnold DM; Rock GA; Clark WF; Barth D; Sutton DM;
Kidney Int Suppl; 2009 Feb; (112):S55-8. PubMed ID: 19180138
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Sadler JE
Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
[TBL] [Abstract][Full Text] [Related]
9. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
Galbusera M; Bresin E; Noris M; Gastoldi S; Belotti D; Capoferri C; Daina E; Perseghin P; Scheiflinger F; Fakhouri F; Grünfeld JP; Pogliani E; Remuzzi G
Blood; 2005 Aug; 106(3):925-8. PubMed ID: 15827129
[TBL] [Abstract][Full Text] [Related]
10. [Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease].
Coppo P; Veyradier A; Monge M;
Presse Med; 2006 Dec; 35(12 Pt 2):1876-86. PubMed ID: 17159713
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
[TBL] [Abstract][Full Text] [Related]
12. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.
Kosugi S; Matsumoto M; Ohtani Y; Take H; Ishizashi H; Fujimura Y; Kuyama J
Int J Hematol; 2005 Jun; 81(5):433-6. PubMed ID: 16158827
[TBL] [Abstract][Full Text] [Related]
13. [Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case].
Ojeda-Uribe M; Brunot A; Issler M
Rev Med Chil; 2005 Nov; 133(11):1349-54. PubMed ID: 16446859
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
[TBL] [Abstract][Full Text] [Related]
15. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor.
Schleinitz N; Ebbo M; Mazodier K; Poullin P; Bernit E; Veit V; Veyradier A; Fakhouri F; Kaplanski G; Harle JR
Am J Hematol; 2007 May; 82(5):417-8. PubMed ID: 17266057
[No Abstract] [Full Text] [Related]
16. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab.
Herbei L; Venugopal P
Clin Adv Hematol Oncol; 2006 Mar; 4(3):215-7; discussion 217-8. PubMed ID: 16728931
[No Abstract] [Full Text] [Related]
17. Immunotherapy for thrombotic thrombocytopenic purpura.
Cataland SR; Wu HM
Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
[TBL] [Abstract][Full Text] [Related]
18. Treatment of thrombotic thrombocytopenic purpura.
van der Straaten M; Jamart S; Wens R; Gottignies P; Dratwa M; Devriendt J
Intensive Care Med; 2005 Apr; 31(4):600. PubMed ID: 15703893
[No Abstract] [Full Text] [Related]
19. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
